BioSpace News Archive

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system disorders, announced that it will participate in Citi’s 15th Annual BioPharma Virtual Conference on September 9, 2020 at 1:30 p.m. Eastern Time.

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to participate in the following virtual investor conferences in September 2020.

Sharps Compliance Corp. (Nasdaq: SMED) announced today that David P. Tusa, Chief Executive Officer has been invited to participate in Barrington Research’s 13th Annual Fall Investment Conference, which will take place virtually on Wednesday, September 9, 2020.

Company plans to further strengthen its regulatory expertise and capabilities as ALS phase 3 clinical trial nears completion in Q4

ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, along with its joint venture, ImmuneCyte, Inc. today announced plans to roll out a comprehensive diagnostic and therapeutic product line to fight the global COVID-19 pandemic. The

Real Time Medical (“RTM” or “the Company”), a leader in developing software platforms that improve the efficiency, quality and speed of medical information sharing between professionals, announced today the launch of an app to help healthcare professionals and the public make better-informed decisions about COVID-19 for their patients, their families and themselves in real time, in one integrated platform.

DILIsym Services, Inc., a Simulations Plus company (Nasdaq: SLP) and a leading provider of modeling and simulation software for pharmaceutical safety and efficacy, today announced that simulations using the DILIsym ® software were utilized as part of the U.S. Food and Drug Administration’s (FDA) review of the safety of

The Blood Profiling Atlas in Cancer Consortium (BloodPAC) published “Generic Protocols for the Analytical Validation of Next-Generation Sequencing-Based ctDNA Assays: A Joint Consensus Recommendation of the BloodPAC’s Analytical Variables Working Group,” in the September 2020 issue of Clinical Chemistry.

Visit BirthControlDoneMyWay.com to learn more about some of the many available contraceptive options I’m So Done is a national unbranded campaign intended to enhance the birth control conversation for women Encourage education on contraceptive care options Facilitate an honest discussion between women and their healthcare providers Spark a social community of likeminded women in the “So Done Club,” reassuring them that they are not alone Join the conversation by participating on

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) and SmartPharm Therapeutics, Inc. (“SmartPharm”) announced today that Sorrento has completed the acquisition of SmartPharm, a gene-encoded protein therapeutics company developing non-viral DNA and RNA gene delivery platforms for COVID-19 and rare diseases with broad potential application in enhancing any antibody-centric therapeutics.